
Rigel Pharmaceuticals (RIGL) Stock Forecast & Price Target
Rigel Pharmaceuticals (RIGL) Analyst Ratings
Bulls say
Rigel Pharmaceuticals has shown strong financial performance, with notable increases in product sales for its key offerings: Tavalisse sales rose by 18% to $31 million, Rezlidhia by 35% to $7.4 million, and Gavretta by 14% to $8.1 million, driven by robust net product sales and increased contract revenues. The company achieved a significant milestone with positive net income in FY2024, indicating progress toward sustained profitability, while ending the year with $77.3 million in cash to support further growth initiatives. Looking ahead, Rigel aims to expand its commercial portfolio and enhance access to its therapies beyond the U.S., positioning the firm well for continued revenue growth and successful trial outcomes in its clinical pipeline.
Bears say
The negative outlook on Rigel Pharmaceuticals's stock is primarily driven by the significant risks associated with ongoing and future clinical trials, which could lead to substantial downward selling pressure if they fail or yield inconclusive results. Additionally, the company's reliance on securing adequate funding to advance its pipeline further complicates its financial stability, particularly if trial outcomes do not meet expectations. Lastly, the limited response depth observed in clinical evaluations, especially for product candidates like R289, raises concerns regarding the overall efficacy and market potential of Rigel's drug offerings.
This aggregate rating is based on analysts' research of Rigel Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Rigel Pharmaceuticals (RIGL) Analyst Forecast & Price Prediction
Start investing in Rigel Pharmaceuticals (RIGL)
Order type
Buy in
Order amount
Est. shares
0 shares